


FSC231

Cat. No.:	HY-117772
CAS No.:	1215849-96-9
Molecular Formula:	C ₁₃ H ₁₀ Cl ₂ N ₂ O ₃
Molecular Weight:	313.14
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FSC231 is a PSD95/DLG/ZO1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects ^[1] .								
IC₅₀ & Target	PICK1 ^[1] .								
In Vitro	FSC231 (50 μM) blocks binding between GluR2 and PICK1 in COS7 cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>FSC231 (78.40 μg/kg in total, daily, seven times, i.p., 3 h before Paclitaxel) alleviates the Paclitaxel (HY-B0015) induced neuralgia of rats^[1].</p> <p>FSC231 (39.2 μg/kg/day, i.p., for 4 weeks) inhibits the development of diabetic cardiomyopathy in rats by inhibiting ROS generation and apoptosis partly via PICK1/eNOS/cGMP pathway^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Paclitaxel (HY-B0015) induced neuralgia of rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>78.40 μg/kg in total</td> </tr> <tr> <td>Administration:</td> <td>i.p., daily, seven times, completed at 3 h before Paclitaxel</td> </tr> <tr> <td>Result:</td> <td>Reversed the changes of inflammatory cytokines (IL6, TNFα and IL10). Inhibited the phosphorylation levels of GSK3β and ERK1/2.</td> </tr> </table>	Animal Model:	Paclitaxel (HY-B0015) induced neuralgia of rats ^[1]	Dosage:	78.40 μg/kg in total	Administration:	i.p., daily, seven times, completed at 3 h before Paclitaxel	Result:	Reversed the changes of inflammatory cytokines (IL6, TNFα and IL10). Inhibited the phosphorylation levels of GSK3β and ERK1/2.
Animal Model:	Paclitaxel (HY-B0015) induced neuralgia of rats ^[1]								
Dosage:	78.40 μg/kg in total								
Administration:	i.p., daily, seven times, completed at 3 h before Paclitaxel								
Result:	Reversed the changes of inflammatory cytokines (IL6, TNFα and IL10). Inhibited the phosphorylation levels of GSK3β and ERK1/2.								

REFERENCES

- [1]. Zhang X, et al. FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2. *Brain Behav.* 2021 Nov;11(11):e2380.
- [2]. Thorsen TS, et al. Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. *Proc Natl Acad Sci U S A.* 2010 Jan 5;107(1):413-8.
- [3]. Cai Fei, et al. GW27-e1146 PICK1 inhibition restores myocardial injury by suppressing reactive oxygen species generation and apoptosis in diabetic rats. *J Am Coll Cardiol.* 2016 Oct, 68 (16_Supplement) C67.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA